Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections

Inactive Publication Date: 2015-03-26
SEQUOIA SCI
View PDF28 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention is a new method for making a stable and effective adjuvant called PHAD, which can be packaged into syringes and shipped without needing to be lyophilized. The PHAD compositions can be sterilized and stored at refrigerated temperatures. The invention also includes the use of a non-ionic surfactant to prevent aggregation or increase in particle size of the PHAD formulations. The preferred adjuvant formulations contain a specific buffer and a synthetically produced phosphatidylcholine. The PHAD formulations are stable and effective when prepared with high purity phosphatidylcholines.

Problems solved by technology

Another issue with vaccines is that vaccines can have a short shelf life and are prone to expire prior to use.
For example, it was reported that as of Jul. 1, 2010 40 million unused doses of swine flu vaccine that cost about $260 million to produce had just expired and were being destroyed.
Vaccine expirations result in significant economic losses each year in the US.
As a result, the mixture of 3′-O-desacyl-4′-monophosphoryl lipid A presents manufacturing, testing, and use challenges that greatly contribute to the expense and supply issues with the vaccine.
In addition to storage problems, vaccine injections are often painful to the recipient.
Redness, swelling, itching and tenderness at injection sites may occur after administration of a vaccine.
The severity of the injection site reactions and systemic reactions are significant requiring medical treatment involving narcotic use, IV hydration, or other physician implemented treatments and loss of work from preventing daily activity due to diarrhea, myalgia, fatigue, headache, and vomiting.
Whether or not a specific adjuvant or combination of adjuvants will enhance an immune response toward each specific antigen is unpredictable.
The failure in the art to identify new therapeutic alternatives to prevent and treat gram-negative bacterial infections is well documented.
The failure to identify new vaccines to prevent and treat bacterial infections is well documented.
Despite recent progress in the epidemiology and pathogenesis of UTI, there have been no recent major improvements in our ability to actually prevent or treat these infections.
UPEC strains that lack the FimH adhesin are unable to effectively colonize the bladder.
The use of FimCH as an antigen in a vaccine is therefore limited by the requirement of an effective adjuvant.
The development of MedImmune's FimCH vaccine with the MF59 adjuvant was discontinued because of these disappointing results.
MF59 with squalene has a history of causing severe local injection site and systemic reactions when used with certain antigens.
The failure of MedImmune and others to develop a UTI vaccine evidences the difficulties of developing new vaccines for bacterial infections.
MedImmune demonstrated that alum does not sufficiently enhance the immune response to FimCH.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
  • Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
  • Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0200]PHAD formulations are manufactured as follows to produce a molar ratio of about 2.5:1 of DPPC to PHAD.

[0201]PHAD, phosphorylated hexaacyl disaccharide, and DPPC can be obtained from Avanti Polar Lipids (Alabaster, Ala., USA) as either non-GMP or GMP material (the Certificate of Analysis is provided in Table 1). PHAD is a synthetic version of monophosphoryl lipid A. PHAD is formulated with DPPC to prepare the adjuvant formulation of the invention. DPPC's release specifications are provided in the table 2. The transition temperature of DPPC is 41° C.

[0202]PHAD is weighed out into an appropriate glass vial, preferably a Type 1 Plus Schott glass vial. An appropriate amount of an approximately 2.3 mg / ml DPPC solution, or equivalent, in ethanol is added. This preparation is sonicated for approximately 1 minute while gently swirling the preparation, and then the ethanol is appropriately removed via evaporation using care. The film is reconstituted with 10 mM trisodium citrate, pH 6.0...

example 2

[0207]Antigens for the vaccine may be prepared as follows.

[0208]FimCH is a non-covalent complex of FimC and FimH recombinant proteins. The recombinant proteins are derived from transgenic E. coli culture. The FimC and FimH proteins are expressed separately in E. coli, and they spontaneously form a non-covalent complex. The molecular weight of the FimCH complex is approximately 51,700 Daltons.

[0209]The FimH protein (SEQ ID No: 1) of the complex has a molecular weight of 29,065 Daltons, and it consists of 279 amino acid residues represented by the sequence below:

Phe Ala Cys Lys Thr Ala Asn Gly Thr Ala Ile ProIle Gly Gly Gly Ser Ala Asn Val Tyr Val Asn LeuAla Pro Val Val Asn Val Gly Gln Asn Leu Val ValAsp Leu Ser Thr Gln Ile Phe Cys His Asn Asp TyrPro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln ArgGly Ser Ala Tyr Gly Gly Val Leu Ser Asn Phe SerGly Thr Val Lys Tyr Ser Gly Ser Ser Tyr Pro PhePro Thr Thr Ser Glu Thr Pro Arg Val Val Tyr AsnSer Arg Thr Asp Lys Pro Trp Pro Val Ala Leu TyrLeu Thr...

example 3

Bioprocessing

Process to Obtain Antigens of the Vaccine

[0214]The bioprocessing step is initiated with inoculation of master cell bank (MCB) into shake flasks containing APS LB medium with kanamycin (50 μg / mL) and chloramphenicol (20 μg / mL). When the OD reaches 2.0-3.0 units (after approximately 15 hours growth), the cell culture is transferred aseptically into reactors for fed-batch fermentation. The medium containing APS Super Broth, about 0.8% glycerol, and antibiotics is sterilized prior to inoculation. FimH protein expression is induced at OD≧10 with IPTG. Five minutes after IPTG addition, FimC protein expression is induced with arabinose. Cells are harvested approximately one hour later. After harvesting, the cells are separated from the media components by continuous or batch centrifugation.

[0215]Protein Recovery

[0216]Recombinant FimCH is expressed in the E. coli periplasm. E. coli, as a gram negative bacteria, possess an inner and an outer lipid bilayer membrane. The space bet...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Timeaaaaaaaaaa
Massaaaaaaaaaa
Login to View More

Abstract

This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims benefit of U.S. Provisional Application No. 61 / 882,498 filed on Sep. 25, 2013, the contents of which are incorporated in its entirety by reference.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The invention provides novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures, and also up to about 37° C., that can be produced at remarkably low costs. These novel adjuvant compositions and formulations are used in vaccines and exhibit superior properties of enhancing immune responses to antigens while causing less severe injection site and systemic reactions. The invention also describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. The invention also provides methods of administration of said novel vaccine formulatio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/39A61K39/108
CPCA61K39/39A61K39/0258A61K2039/545A61K2039/55511A61K2039/55572A61K9/0019A61K9/19A61K47/24Y02A50/30
Inventor ELDRIDGE, GARYMARTIN, STEVEN M
Owner SEQUOIA SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products